Savara to Present at the Jefferies Virtual Healthcare Conference

Rhea-AI Summary

Savara Inc. (Nasdaq: SVRA), a biopharmaceutical company specializing in rare respiratory diseases, has announced its participation in the Jefferies Virtual Healthcare Conference. The presentation is scheduled for June 2, 2021, at 10:00 AM ET. Interested parties can access the live audio webcast on Savara's Investors page, with an archived version available for 90 days post-event. The company’s primary focus is on its molgramostim nebulizer solution, currently in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Savara management will be presenting at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 10:00 AM ET / 7:00 AM PT.

Interested parties can access a live audio webcast on the Investors page of the Savara website at www.savarapharma.com/investors/events-presentations/. Please connect to the Company's website at least 15 minutes prior to the start of the presentation to ensure sufficient time for any software download that may be required for the webcast. An archived presentation will be available on Savara's website for 90 days.

About Savara

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com. (Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).

View source version on businesswire.com: https://www.businesswire.com/news/home/20210526005352/en/

FAQ

What is Savara Inc. presenting at the Jefferies Virtual Healthcare Conference?

Savara Inc. will present information regarding their developments in rare respiratory diseases, specifically focusing on their lead program, molgramostim nebulizer solution, on June 2, 2021.

When is Savara's presentation scheduled at the Jefferies Virtual Healthcare Conference?

Savara's presentation is scheduled for June 2, 2021, at 10:00 AM ET.

How can I access Savara's presentation at the Jefferies Conference?

You can access the live audio webcast of Savara's presentation on their Investors page at www.savarapharma.com/investors/events-presentations/.

What is molgramostim nebulizer solution being developed by Savara?

Molgramostim nebulizer solution is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).

Will Savara's presentation be available after the event?

Yes, an archived version of the presentation will be available on Savara's website for 90 days after the event.